Mylan Pharmaceuticals Inc. et al. vs. Regeneron Pharmaceuticals, Inc.
Explore the PTAB proceeding IPR2021-00880 filed by Mylan Pharmaceuticals Inc. et al. on 2021-05-05. This includes filing dates, application numbers, tech centers, patent numbers, and current case status.
Proceeding Overview
Proceeding Number
IPR2021-00880
Filing Date
2021-05-05
Accorded Filing Date
2021-05-05
Institution Decision Date
2021-11-10
Last Modified Date
2024-07-19
Proceeding Type
IPR
Termination Date
2022-11-09
Trial Status
Final Written Decision
Parties & Counsel
Petitioner
Mylan Pharmaceuticals Inc. et al.
Represented By
Molino, Paulet alPatent Owner / Respondent
Regeneron Pharmaceuticals, Inc.
Represented By
Fishman, Deborahet alPatent Information
Tribunal & APJ Panel Intelligence
Tribunal
Patent Trial and Appeal Board (USPTO)
Technology Center
TC 1600 - Biotechnology & Organic Chemistry
Decisions Rendered
3 Total
Proceeding Status
Final Written Decision
Administrative Patent Judges (APJ Panel)
Board Decisions & Rulings (3)
Address and Attorney/Agent Information
Power of Attorney & Correspondence
Attorney / Agent Information
| Reg # | Name | Phone |
|---|---|---|
| 41408 | David Marsh | +1 202-942-5068 |
| 48001 | Thomas Triolo | +1 914-847-1612 |
| 48921 | Stephen Gaudet | +1 914-847-7376 |
| 50370 | Neil Miyamoto | +1 914-847-7175 |
| 50437 | Frank Cottingham | +1 914-593-1116 |
| 58583 | Brian Cocca | +1 914-847-1421 |
| 58714 | Ilona Gont | +1 914-847-1304 |
| 59668 | Brandon Schurter | +1 914-847-7000 |
Global Patent Family Cross-Litigation Radar
CasLoc 360ยฐ Radar 18 Family MembersMulti-jurisdiction dispute tracking across USPTO PTAB, U.S. Federal Courts, Unified Patent Court (UPC), and EPO Oppositions
| Jurisdiction | Publication Number | Relationship | Official Record |
|---|---|---|---|
| ๐บ๐ธ United States | US 9,669,069 B2 Asserted | US Continuation / Sibling | View Official Patent → |
| ๐บ๐ธ United States | US 10,130,681 B2 | US Continuation / Sibling | View Official Patent → |
| ๐บ๐ธ United States | US 10,857,205 B2 | US Continuation / Sibling | View Official Patent → |
| ๐บ๐ธ United States | US 10,828,345 B2 | US Continuation / Sibling | View Official Patent → |
| ๐บ๐ธ United States | US 10,888,601 B2 | US Continuation / Sibling | View Official Patent → |
| ๐บ๐ธ United States | US 11,986,511 B2 | US Continuation / Sibling | View Official Patent → |
| ๐บ๐ธ United States | US 11,730,794 B2 | US Continuation / Sibling | View Official Patent → |
| ๐บ๐ธ United States | US 11,975,045 B2 | US Continuation / Sibling | View Official Patent → |
| ๐บ๐ธ United States | US 11,707,506 B2 | US Continuation / Sibling | View Official Patent → |
| ๐บ๐ธ United States | US 11,253,572 B2 | US Continuation / Sibling | View Official Patent → |
| ๐บ๐ธ United States | US 11,559,564 B2 | US Continuation / Sibling | View Official Patent → |
| ๐บ๐ธ United States | US 12,268,730 B2 | US Continuation / Sibling | View Official Patent → |
| ๐บ๐ธ United States | US 2025015266 | US Continuation / Sibling | View Official Patent → |
| ๐บ๐ธ United States | US 2011614322 | US Continuation / Sibling | View Official Patent → |
| ๐บ๐ธ United States | US 2011614348 | US Continuation / Sibling | View Official Patent → |
Fresenius Kabi SwissBiosim, GmbH et al. v. Regeneron Pharmaceuticals, Inc.
Biocon Biologics Inc. et al. v. Regeneron Pharmaceuticals, Inc.
Celltrion, Inc. et al. v. Regeneron Pharmaceuticals, Inc.
Biocon Biologics Inc. et al. v. Regeneron Pharmaceuticals, Inc.
Samsung Bioepis Co., Ltd. v. Regeneron Pharmaceuticals, Inc.
Samsung Bioepis Co., Ltd. v. Regeneron Pharmaceuticals, Inc.
Samsung Bioepis Co., Ltd. v. Regeneron Pharmaceuticals, Inc.
Celltrion, Inc. et al. v. Regeneron Pharmaceuticals, Inc.
Celltrion, Inc. et al. v. Regeneron Pharmaceuticals, Inc.
Samsung Bioepis Co., Ltd. v. Regeneron Pharmaceuticals, Inc.